Inventor · disambiguated record
Dwight Morrow
Also filed as: MORROW DWIGHT · MORROW DWIGHT M
4 granted patents·17 pending applications·22 citations·filing 2001–2024
73Inventor score
Files withMAGENTA THERAPEUTICS INC15ENSOMA INC2SCHEPENS EYE RES INST1SMITHKLINE BEECHAM CORP & SMIT1VOR BIOPHARMA INC1
Top patents by PatentIndex Score
21 records- 0189US10111966B2Methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Oct 30, 2018·12 cites·16 claims
- 0286US10058573B1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·7 cites·9 claims
- 0384US10624973B2Methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Apr 21, 2020·2 cites·26 claims
- 0482US2024408168A1Compositions and methods for the depletion of cellsVOR BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0580US2024207428A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0679US2025295698A1Dosing regimens for the mobilization of hematopoietic stem cellsENSOMA INC·Filed 2024·Application pending·0 cites
- 0777US11260079B2Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·1 cites·23 claims
- 0873US2025032549A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsENSOMA INC·Filed 2024·Application pending·0 cites
- 0972US2023130646A1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1065US2020376134A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1163US2021162063A1Compositions and methods for the depletion of cd117+ cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1263US2019328901A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1363US2022096559A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1460US2019336536A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1556US2023330185A1Methods and compositions for transducing hematopoietic stem and progenitor cells in vivoMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1656US2019167726A1Dosing Regimens for the Mobilization of Hematopoietic Stem CellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1753US2019134217A1Compositions and methods for the depletion of cd117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1852US2022401481A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1945US2004043393A1AXOR35, a G-protein coupled receptorFiled 2003·Application pending·0 cites
- 2042US2002137054A1AXOR35, a G-protein coupled receptorSMITHKLINE BEECHAM CORP & SMIT·Filed 2001·Application pending·0 cites
- 2139US2018228811A1Gdnf induction for the treatment of retinal disordersSCHEPENS EYE RES INST·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →